Phio Q3 net loss $3.6M, cash $14.5M; appoints Bitterman, Mahoney, Spellman

Phio Pharmaceuticals Corp.

2022-Q3 EPS reported -$0.64

New appointments: Robert Bitterman as Interim Executive Chairman, Linda Mahoney as VP of Project Development, Dr. Mary Spellman as medical advisor.
Cash at Sept 30, 2022: $14.5M, down from $24.1M at Dec 31, 2021; expects to fund operations for at least 12 months.
Net loss $3.6M ($0.26/share) vs $3.7M ($0.28) in Q3 2021; R&D expenses down 6% to $2.5M.
Phase 1b study of PH-762 for advanced melanoma continues enrollment; top-line data expected Q1 2023.
Plans to initiate trial with AgonOx in Q4 2022; IND-enabling studies for PH-894 by year end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2022 results: net income approximately $3.6 million, or $0.26 per share, EPS $0.26 per share.

Period: the quarter ended September 30, 2022
Net income: approximately $3.6 million, or $0.26 per share
EPS: $0.26 per share
Result: reported results

Exact text from the filing

Net loss decreased 4% to approximately $3.6 million, or $0.26 per share, for the quarter ended September 30, 2022, compared with $3.7 million, or $0.28 per share, for the quarter ended September 30, 2021.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-22-007530

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.